

Please try another search
BioCryst (NASDAQ:BCRX) Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately.“I am honored to succeed Bob...
BioCryst (NASDAQ:BCRX) Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a...
BioCryst (NASDAQ:BCRX) Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO® (berotralstat) for the...
Investing.com - BioCryst (NASDAQ: BCRX) reported fourth quarter EPS of $-0.38, $0.21 worse than the analyst estimate of $-0.17. Revenue for the quarter came in at $79.5M versus the consensus estimate...
BioCryst Pharma (NASDAQ:BCRX) reported Q4 EPS of ($0.40), $0.23 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $79.5 million versus the consensus estimate of $75.57...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review